Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Teva Pharmaceutical Industries Ltd. (TEVA) had Revenue of $16.54B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$16.54B
Net Income	$-1.64B
Cost of Goods Sold	$8.48B
Gross Profit	$8.06B
Operating Expenses	$16.85B
Operating Income	$-303.00M
Non-Operating Income/Expense	$-981.00M
Pre-Tax Income	$-1.28B
Normalized Pre-Tax Income	$-1.28B
Income after Taxes	$-1.96B
Income from Continuous Operations	$-1.96B
Consolidated Net Income/Loss	$-1.96B
Normalized Income after Taxes	$-1.96B
EBIT	$-303.00M
EBITDA	$756.00M
Weighted-Average Shares Outstanding (Basic)	1.13B
Weighted-Average Shares Outstanding (Diluted)	1.13B
Earnings per Share (EPS) (Basic)	$-1.45
Earnings per Share (EPS) (Diluted)	$-1.45
Balance Sheet Financials
Current Assets	$12.55B
Property, Plant, and Equipment	$4.58B
Long-Term Assets	$26.77B
Total Assets	$39.33B
Current Liabilities	$12.80B
Long-Term Debt	$16.00B
Long-Term Liabilities	$21.15B
Total Liabilities	$33.95B
Common Equity	$5.38B
Tangible Shareholders Equity	$-14.19B
Shareholders Equity	$5.38B
Common Shares Outstanding	1.13B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.25B
Cash Flow from Investing Activities	$792.00M
Cash Flow from Financial Activities	$-1.79B
Beginning Cash	$3.23B
End Cash	$3.30B
Increase/Decrease in Cash	$73.00M
Stock-Based Compensation	$123.00M
Common Stock Dividends Paid	$-78.00M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.98
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.75
Debt to Equity Ratio	3.31
Gross Margin	48.74%
Operating Margin	-1.83%
EBIT Margin	-1.83%
EBITDA Margin	4.57%
Pre-Tax Profit Margin	-7.76%
Profit Margin	-9.91%
Free Cash Flow	$792.00M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.42
Inventory Turnover	2.82
Receiveable Turnover	5.41
Days Sales in Receivables	67.49
Return on Equity	-36.41%
Return on Tangible Equity	13.81%
Return on Assets	-4.98%
Return on Investments	-9.16%
Book Value Per Share	$4.75
Free Cash Flow per Share	$0.70
Operating Cash Flow per Share	$1.10

Data from Zacks Investment Research, Inc.